|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2014-01-01 |
|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2014-01-01 |
|
|
|
|
|
|
最高研发阶段批准上市 |
首次获批国家/地区- |
首次获批日期- |
A phase III, randomized, two-armed, double-blind, parallel, active-controlled, non-inferiority clinical trial to compare efficacy and safety of Vedolizumab (AryoGen) versus Vedolizumab (Entyvio®, Takeda Inc.) in patients with moderate-to-severe Ulcerative Colitis between 18 to 75 years
A Randomized, Two-armed, Double-blind, Single-dose, Crossover, Two-sequence, Bioequivalence Clinical Trial to Compare PK Parameters and Safety of rFVIII-Fc (AryoGen Pharmed Co.) Versus Elocta® in PTPs With Severe Hemophilia A
The study is designed as a randomized, two-armed, double-blind, single-dose, crossover, two-sequence, active-controlled, multi-center, bioequivalence clinical trial with a primary endpoint of dose-normalized area under the curve (dnAUC last)
A phase 3, randomized, multicenter, double-blind, two-armed, parallel, active-controlled, equivalency clinical trial to compare efficacy and safety of Temziva (Tocilizumab produced by AryoGen Pharmed) versus Actemra® (Tocilizumab produced by Genentech-Roche co.) in patients with active moderate to severe rheumatoid arthritis
100 项与 Aryogen Pharmed 相关的临床结果
0 项与 Aryogen Pharmed 相关的专利(医药)
100 项与 Aryogen Pharmed 相关的药物交易
100 项与 Aryogen Pharmed 相关的转化医学